Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022

SELL
$5.17 - $7.11 $1,323 - $1,820
-256 Reduced 0.72%
35,119 $195,000
Q2 2022

Aug 01, 2022

BUY
$3.41 - $8.95 $136 - $358
40 Added 0.11%
35,375 $184,000
Q1 2022

May 04, 2022

SELL
$7.78 - $15.31 $1.08 Million - $2.12 Million
-138,622 Reduced 79.69%
35,335 $212,000
Q4 2021

Feb 07, 2022

BUY
$14.25 - $23.53 $525,483 - $867,692
36,876 Added 26.9%
173,957 $2.59 Million
Q3 2021

Nov 02, 2021

SELL
$16.88 - $22.38 $20,813 - $27,594
-1,233 Reduced 0.89%
137,081 $2.59 Million
Q2 2021

Aug 03, 2021

SELL
$18.03 - $23.82 $143,518 - $189,607
-7,960 Reduced 5.44%
138,314 $2.57 Million
Q1 2021

May 04, 2021

BUY
$20.29 - $27.54 $2,597 - $3,525
128 Added 0.09%
146,274 $3.33 Million
Q4 2020

Feb 01, 2021

BUY
$10.16 - $23.98 $48,534 - $114,552
4,777 Added 3.38%
146,146 $3.17 Million
Q3 2020

Nov 09, 2020

SELL
$7.44 - $13.15 $146,835 - $259,528
-19,736 Reduced 12.25%
141,369 $1.42 Million
Q2 2020

Aug 07, 2020

BUY
$7.24 - $11.05 $736,908 - $1.12 Million
101,783 Added 171.58%
161,105 $1.25 Million
Q1 2020

May 04, 2020

BUY
$6.19 - $12.16 $344,541 - $676,837
55,661 Added 1520.38%
59,322 $605,000
Q4 2019

Feb 06, 2020

SELL
$8.15 - $11.39 $455,625 - $636,757
-55,905 Reduced 93.85%
3,661 $40,000
Q4 2019

Feb 04, 2020

BUY
$8.15 - $11.39 $441,159 - $616,540
54,130 Added 995.77%
59,566 $610,000
Q3 2019

Nov 12, 2019

BUY
$7.91 - $11.76 $14,040 - $20,874
1,775 Added 48.48%
5,436 $49,000
Q2 2019

Aug 15, 2019

SELL
$9.69 - $12.23 $22,664 - $28,605
-2,339 Reduced 38.98%
3,661 $42,000
Q3 2018

Nov 01, 2018

BUY
$15.0 - $15.2 $90,000 - $91,200
6,000 New
6,000 $90,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $106M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.